RUNAT-BI: A Ruthenium(III) Complex as a Selective Anti-Tumor Drug Candidate against Highly Aggressive Cancer Cell...

Area of Science:

• Medicinal Chemistry
• Cancer Biology
• Pharmacology

Background:

• Ruthenium compounds show promise in cancer therapy, offering alternatives to platinum-based drugs.
• The precise structure-activity relationship of ruthenium compounds in cancer treatment remains under investigation.
• Runat-BI is a Ru(III) compound formulated with 2,2'-biimidazole.

Purpose of the Study:

• To evaluate the antitumoral activity of racemic Runat-BI and one of its isomers.
• To assess the compound's effects on cancer cell viability, migration, proliferation, and apoptosis.
• To determine the selectivity of Runat-BI against tumor cells compared to non-tumoral cells.

Main Methods:

• Tested racemic Runat-BI and an isolated isomer against eight cancer cell lines (breast, colon, gastric) and one non-tumoral cell line.
• Performed time- and dose-dependent assays for cell viability, migration, and proliferation.
• Analyzed the expression of pro- and antiapoptotic genes and measured cell growth rate and doubling time.

Main Results:

• Racemic Runat-BI significantly reduced viability and migration in fast-proliferating breast, colon, and gastric cancer cell lines.
• The compound exhibited selectivity, showing greater impact on tumor cells than non-tumoral cells.
• Runat-BI treatment led to increased expression of proapoptotic genes.
• The isolated isomer of Runat-BI showed no significant antitumoral effect.

Conclusions:

• Racemic Runat-BI is a potential therapeutic candidate for aggressive tumors.
• Further research is needed to elucidate the role of individual isomers and the precise mechanism of action.
• The findings support the development of Runat-BI for targeted cancer treatment strategies.